GlaxoSmithKline
GlaxoSmithKline and Pfizer to create a new world-leading, specialist HIV company
GlaxoSmithKline and Stiefel to create new world-leading specialist dermatology business
http://www.gsk.com/about/history.htm
| 1830
John K Smith opens his first drugstore in Philadelphia. John's younger brother, George, joins him in 1841 to form John K Smith & Co. |
1842
Thomas Beecham launches the Beecham's Pills laxative business in England. The laxative is to become widely successful. |
||
| 1865
Mahlon Kline joins Smith and Shoemaker - as John K Smith and Co had become - as a bookkeeper. |
1859 Beecham opens the world's first factory to be built solely for making medicines at St Helens in England. |
1873
Joseph Nathan, who left the UK to seek new business opportunities 20 years before, establishes a general trading company at Wellington in New Zealand - Joseph Nathan and Co - the foundation for the Glaxo company to be formed later. |
1880
Burroughs Wellcome & Company is established in London by American pharmacists Henry Wellcome and Silas Burroughs, four years after Joseph Nathan opened a London office. |
| 1875
Mahlon Kline took on additional responsibilities as a salesman and added many new and large accounts. He is rewarded when the company, Mahlon K Smith and Company, is renamed Smith, Kline and Company. |
1885
Thomas Beecham's company acquires headquarters on the corner of Silver Street and Water Street, St Helens, England. Two years later, the company's new factory in St Helens becomes the first in the area to have electricity. |
1884 Tabloid is registered as a Burroughs Wellcome and Company trademark to describe its compressed tablets. |
|
| 1891
Smith, Kline and Company acquires French, Richards and Company, providing a greater portfolio of consumer brands. |
1906
Glaxo is registered by Joseph Nathan and Co as a trademark for dried milk. |
1902
The Wellcome Tropical Research Laboratories open. |
|
| 1929 Smith, Kline and French Company is renamed Smith Kline and French Laboratories and becomes more focused on research. | 1947
Glaxo Laboratories Ltd absorbs the Joseph Nathan company
and becomes the parent company. Glaxo is listed on the
London Stock Exchange. |
1936 Sir Henry Wellcome's will leaves sole ownership of The Wellcome Foundation Ltd to a UK medical research charity, today called the Wellcome Trust. Sir Henry Dale of Wellcome is awarded the Nobel Prize for Medicine for his work in the chemical transmission of nerve impulses. | |
| 1958
Glaxo acquires Allen and
Hanburys Ltd. |
|||
| 1982 SmithKline acquires Allergan, an eye and skincare business, and merges with Beckman Instruments Inc, a company specialising in diagnostics and measurement instruments and supplies. The company is renamed SmithKline Beckman. | 1978 Through the acquisition of Meyer Laboratories Inc, Glaxo’s business in the US is started, to become Glaxo Inc from 1980. The broad-spectrum injectable antibiotic Zinacef (cefuroxime) is introduced by Glaxo. | ||
| 1989 SmithKline Beckman and The Beecham Group plc merge to form SmithKline Beecham plc. | 1995 Glaxo and Wellcome merge to form Glaxo Wellcome. | ||
| 2000 GlaxoSmithKline formed through the merger of Glaxo Wellcome and SmithKline Beecham. | |||
April 16, 2009 GlaxoSmithKline
GlaxoSmithKline and Pfizer announce innovative agreement to create a new world-leading, specialist HIV company
GlaxoSmithKline plc (GSK) and Pfizer Inc (PFE) today announced they have entered into an agreement to create a new world-leading HIV company focused solely on research, development and commercialisation of HIV medicines. The new HIV business will be more sustainable and broader in scope than either company's individually, and will hold a 19% share of the growing market and have an industry-leading pipeline. GSK will initially hold an 85% equity interest in the new company and Pfizer will hold 15%.
Focused new business with
industry-leading HIV pipeline
The new company will have a broad product portfolio of 11
marketed products
including market-leading therapies such as Combivir, Kivexa and
Selzentry/Celsentri. Based on 2008 pro-forma results, this
combined portfolio generated sales of
approximately £1.6 billion and these revenues will provide
the new company with financial stability and support investment
in its pipeline.
The clear focus of the new business will be to invest in research and development of innovative HIV treatments and formulations that improve adherence and overcome resistance to the virus.
The company will have an industry-leading pipeline of 6 innovative and targeted medicines, including 4 compounds in phase II development. Altogether, the new company will have 17 molecules at its disposal to develop in fixed-dose combinations as possible new HIV treatments. The new company will contract R&D services directly from GSK and Pfizer to develop these medicines.
日本経済新聞
新会社はＨＩＶ関連薬で計11製品をそろえ、売上高は24億ドル（約2400億円）にのぼる。２ケタ成長が見込める抗ＨＩＶ薬市場ではシェア19％を握る大手となる。新薬候補物質も6品目あり、うち4品目が開発中期の段階にある。
ＧＳＫは主力の抗ウイルス事業を強化。ファイザーは同業の米ワイス買収で補強したバイオ医薬品の開発に集中する。
GlaxoSmithKline and
Stiefel to create new world-leading specialist dermatology
business 皮膚科
Stiefel, the
world’s largest independent dermatology
company, acquired by GSK in deal valued at up to $3.6 billion
New
global business will have combined revenues of approximately $1.5
billion and robust new product pipeline
Significant
step forward to grow and diversify GSK’s business, providing immediate
new revenue and synergy opportunities
GlaxoSmithKline plc (GSK) and Stiefel Laboratories Inc. today
announced that they have signed an agreement to create a new
world-leading specialist dermatology business. Under the terms of
the agreement GSK will acquire the total share capital of Stiefel
for a cash consideration of $2.9 billion. GSK also expects to
assume $0.4 billion of net debt upon closing. A potential further
$0.3 billion cash payment is contingent on future performance.
GSK’s existing prescription
dermatological products will be combined with Stiefel’s and the new specialist global
business will operate under the Stiefel identity within the GSK
Group.